Evidence map›Paper›PMID 38698958›Full record

ArticleActa naturae

Dimeric Bis-Benzimidazole-Pyrroles DB2Py(n) - AT-Site-Specific Ligands: Synthesis, Physicochemical Analysis, and Biological Activity.

O Y Susova, S S Karshieva, A A Kostyukov, N I Moiseeva, E A Zaytseva, K V Kalabina, E Zusinaite, K Gildemann, N M Smirnov, A F Arutyunyan and 1 more

Abstract read
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

O Y SusovaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
S S KarshievaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
A A KostyukovEmanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119334 Russian Federation.
N I MoiseevaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
E A ZaytsevaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
K V KalabinaN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
E ZusinaiteTartu University Institute of Technology, Tartu, 50411 Estonia.
K GildemannTartu University Institute of Technology, Tartu, 50411 Estonia.
N M SmirnovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation.
A F ArutyunyanEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation.
A L ZhuzeEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Its broad spectrum of biological activity makes benzimidazole a fundamental pharmacophore in pharmaceutics. The paper describes newly synthesized AT-specific fluorescent bis-benzimidazole molecules DB2Py(n) that contain a pyrrolcarboxamide fragment of the antibiotic drug netropsin. Physico-chemical methods using absorption, fluorescence, and circular dichroism spectra have shown the ability of bis-benzimidazole- pyrroles to form complexes with DNA. The new DB2Py(n) series have turned out to be more toxic to human tumor lines and less vulnerable to non-tumor cell lines. Bis-benzimidazole-pyrroles penetrated the cell nucleus, affected the cell-cycle synthesis (S) phase, and inhibited eukaryotic topoisomerase I in a cellfree model at low concentrations. A real-time tumor cell proliferation test confirmed the molecule's enhanced toxic properties upon dimerization. Preliminary cytotoxicity data for the bis-benzimidazole-pyrroles tested in a cell model with a MDR phenotype showed that monomeric compounds can overcome MDR, while dimerization weakens this ability to its intermediate values as compared to doxorubicin. In this respect, the newly synthesized cytotoxic structures seem promising for further, in-depth study of their properties and action mechanism in relation to human tumor cells, as well as for designing new AT-specific ligands.

Indexed as

bis-benzimidazole-pyrrolecell cyclecytotoxicityDNA-bindingDNA narrow groove binding ligandmultidrug resistancetopoisomerase I

Identifiers

PMID38698958
PMCPMC11062108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.